Study Details
Full Title
DNA12: A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate
the Safety and Preliminary Efficacy of TRX319 in Subjects
with Primary or Secondary Progressive Multiple Sclerosis
the Safety and Preliminary Efficacy of TRX319 in Subjects
with Primary or Secondary Progressive Multiple Sclerosis
Principal Investigator
Suma
Shah
Protocol Number
PRO00119500
NCT ID
NCT07477639
Phase
I/II
Enrollment Status
Open to Enrollment